Marie Alt

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Journal: Investigational new drugs

Published: June 13, 2021

Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial.

Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial.

Journal: JCO precision oncology

Published: October 19, 2018

Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie.

Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie.

Journal: ESMO open

Published: February 08, 2018

Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians.

Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians.

Journal: Cancer treatment reviews

Published: January 01, 2018

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors.

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 02, 2017

Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial.

Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 21, 2016

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: November 14, 2016

Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials.

Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials.

Journal: Journal of the National Cancer Institute

Published: July 21, 2015

Designs of preoperative biomarkers trials in oncology: a systematic review of the literature.

Designs of preoperative biomarkers trials in oncology: a systematic review of the literature.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 16, 2015

Challenges for the implementation of high-throughput testing and liquid biopsies in personalized medicine cancer trials.

Challenges for the implementation of high-throughput testing and liquid biopsies in personalized medicine cancer trials.

Journal: Personalized medicine

Published: July 01, 2014

The spectrum of clinical trials aiming at personalizing medicine.

The spectrum of clinical trials aiming at personalizing medicine.

Journal: Chinese clinical oncology

Published: February 25, 2014

Showing 1-11 of 11

Last Updated: 09/26/2026